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Abstract
Background—Few studies have examined the effectiveness of full vs. partial vaccination with 
inactivated trivalent influenza vaccines (IIV3) as defined by the U.S. CDC Advisory Committee on 
Immunization Practices (ACIP).
Methods—Respiratory swabs were collected from outpatients aged 6 months to 8 years with 
acute cough for ≤7 days in clinics in 5 states during the 2011–2012 and 2012–2013 influenza 
seasons. Influenza was confirmed by real-time reverse transcription polymerase chain reaction 
assay. Receipt of current season IIV3 and up to 4 prior vaccinations was documented from medical 
records and immunization registries. Using a test-negative design, vaccine effectiveness (VE) was 
estimated adjusting for age, race/ethnicity, medical conditions, study site, and month of 
enrollment.
Results—We did not observe higher VE for children fully vs. partially vaccinated with IIV3, as 
defined by U.S. ACIP, though our sample of partially vaccinated children was relatively small. 
However, among children aged 2–8 years in both seasons and against A(H3N2) and B influenza 
illness separately, VE point estimates were consistently higher for children who had received 2 
doses in the same prior season compared to those without (VE range of 58–80% vs. 33–44%, 
respectively). Across seasons, the odds of A(H3N2) illness despite IIV3 vaccination were 2.4-fold 
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(95% CI = 1.4–4.3) higher among children who had not received 2 doses in the same prior season. 
We also noted residual protection among unvaccinated children who were vaccinated the previous 
season (VE range = 36–40% across outcomes).
Conclusion—Vaccination with IIV3 may provide preventive benefit in subsequent seasons, 
including possible residual protection if vaccination is missed. Two vaccine doses in the same 
season may be more effective than alternative priming strategies.
Young children are especially vulnerable to influenza virus infections and along with older 
adults are the most likely to suffer secondary complications and be hospitalized due to 
influenza illness [1–5]. However, relatively few studies have examined the effectiveness of 
inactivated trivalent influenza vaccines (IIV3) in this age group [6, 7]. Over the last decade, 
the Advisory Committee on Immunization Practices (ACIP) of the CDC in the United States 
(U.S.) has progressively expanded who should receive annual influenza vaccination. Groups 
targeted for vaccination expanded from high-risk children only to including all children aged 
6–23 months (starting as “encouraged when feasible” in 2002 and recommended since 2004) 
[8–10], children aged 6–59 months (since 2006) [11], and children aged 6 months to 18 
years (since 2008) [12].
ACIP recommends that children aged 6 months to 8 years receive 2 doses of influenza 
vaccine if they are previously unvaccinated; in 2010, ACIP revised their recommendations to 
ensure 2 prior doses containing the A(H1N1)pdm09 virus component (Supplemental Figure 
A). Admittedly, evidence that can inform these recommendations is limited [6, 7, 13]. 
Improved immunogenicity following 2 doses of IIV3 has been noted, especially among 
vaccine naïve infants and toddlers, but the findings have not been consistent for children 
aged ≥2 years or for all vaccine components [14–20].
Findings from observational studies regarding vaccine effectiveness (VE) in preventing 
laboratory-confirmed influenza outcomes have also been mixed. Some studies have reported 
significant VE for fully vaccinated children only [21–24], while others have observed 
similar VE for fully and partially vaccinated children in some age groups [23, 25–28]. Most 
of these studies have examined VE against all circulating influenza strains [21, 23, 25, 26]; 
few have been able to consider the importance of full vaccination against a specific influenza 
type or subtype [19, 24, 27, 29, 30].
Interpreting these findings is difficult because the criteria for full and partial vaccination 
consist of a variety of potential vaccine exposures. Children who received 2 doses within the 
same season (4 weeks apart) have consistently been described as fully vaccinated. However, 
a single dose can also result in full vaccination depending on vaccination history [11, 31–
34]. Until 2007, a child with a single current season dose and at least 1 previous seasonal 
influenza vaccine dose was considered fully vaccinated. After 2007, a single current season 
dose after 2 or more doses in previous seasons (in specific combinations that have been 
updated each season by ACIP) constituted full vaccination [11, 31–34]. The definition of 
“unvaccinated” also varies across studies, with some categorizing partially vaccinated 
children as unvaccinated [35]. Thus, it is difficult to determine the preventive benefit of 
particular vaccination schedules from VE studies as typically reported.
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The U.S. Influenza Vaccine Effectiveness (Flu VE) Network conducts annual evaluations of 
VE of seasonal influenza vaccines in preventing outpatient medical care for acute respiratory 
illness (ARI) with laboratory-confirmed influenza virus infections [21, 36]. In this study, we 
examine the VE of IIV3 against medically attended influenza ARI among children aged 6 
months to 8 years during the relatively mild 2011–2012 influenza season [37] and the 
moderately severe 2012–2013 season in the U.S. [38].
Specifically, our study has three aims. First, we estimate VE of full and partial IIV3 
vaccination using the ACIP criteria for the two seasons. We improve upon our previous VE 
reports for this age group by limiting our analysis to IIV3 and excluding trivalent live 
attenuated influenza vaccine (LAIV3) [21, 36], by considering prior doses received during 
multiple previous seasons [21], and by reporting VE for both fully and partially vaccinated 
children in both seasons [36]. Second, we estimate VE of IIV3 by the number of current 
season doses and by alternative definitions of priming that consider doses received in the 
previous season, doses received across multiple prior seasons, and receipt of 2 doses in at 
least one prior season. Third, we estimate VE against A(H3N2) and B influenza virus 
illnesses separately.
MATERIALS & METHODS
Subject Enrollment
Details of the U.S. Flu VE Network’s methodology and enrollment during the 2011–2012 
[21] and 2012–2013 season [36] have been previously published. Patients seeking outpatient 
medical care for an ARI (onset ≤7 days) with cough were recruited by study staff in five 
states (Michigan, Pennsylvania, Texas, Washington, and Wisconsin). Consenting parents 
completed an enrollment interview to provide patient and household information. Patient’s 
history of high risk medical conditions was confirmed by extraction from medical records. 
Combined nasal and throat specimens (or nasal specimens only for children aged <2 years) 
were tested for influenza at network laboratories, using real-time reverse transcription 
polymerase chain reaction (RT-PCR). The study was reviewed and approved by the 
institutional review boards at each Network site.
Vaccine Effectiveness
Influenza vaccination status for the study season and for prior seasons was documented from 
medical records and immunization registries. Participants with indeterminate current season 
vaccination status (with illness onset <14 days from vaccination or receipt of a second dose 
of vaccine <28 days from the first dose) and those who received LAIV3 during the study 
season were excluded. For both seasons, we extracted dates of IIV3 vaccination for the 
current study season, up to 3 doses of any influenza vaccine from previous seasons, and the 
earliest recorded influenza vaccination. Thus, up to 4 prior season doses were documented, 
but this likely underestimated the number of children who received 2 prior doses within the 
same prior season, especially among repeatedly vaccinated older children.
Because we could not distinguish between seasonal and monovalent A(H1N1)pdm09 
vaccines in 2009, we considered doses after October 1, 2009 as monovalent A(H1N1)pdm09 
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vaccines; monovalent vaccine was introduced and seasonal vaccination declined in early 
October [39, 40]. Receipt of the monovalent vaccine was considered as it applied to ACIP 
criteria, but it was not included in the count of prior seasonal vaccinations. There was little 
change in the percentage of primed children or in our VE results when we used alternative 
November and December cut-offs for counting monovalent A(H1N1)pdm09 vaccinations.
For the 2012–2013 season only, we were able to confirm whether the child had consistently 
been enrolled in the site’s health system since 6 months of age. For this season, we excluded 
children aged <2 years who lacked medical records going back at least 1 year and excluded 
children 2–8 years without records going back at least 2 years.
Vaccine components for the study years and prior seasons are listed in Supplemental Table 
A; the A(H3N2) and B influenza virus components changed from 2011–2012 to 2012–2013 
[37]. The vast majority of tested circulating viruses in the U.S. were antigenically similar to 
vaccine prototype components during both seasons [37, 38]. However, antigenic differences 
were noted between circulating viruses and the egg-adapted A(H3N2) strain in the 2012–13 
vaccine [41].
Influenza VE is assessed using a test-negative design [42, 43], whereby VE equals 100% × 
(1-odds ratio [ratio of odds of vaccination among influenza-positive cases to the odds of 
vaccination among influenza-negative controls]) using logistic regression. Similar to 
previous VE estimates for this Network [21, 25, 36], adjusted models included values for 
age [months], race/ethnicity, high-risk medical conditions, days from illness onset to 
specimen collection, study site, and calendar time [month of enrollment]. Statistically 
significant or non-zero VE is indicated by a 95% confidence interval (CI) that does not 
overlap with zero.
We define full and partial vaccination using the ACIP criteria for each study season [34, 44] 
(Supplemental Figure A). We then examine VE using four definitions of vaccine priming: ≥1 
doses of any influenza vaccine during the prior season, ≥1 doses recorded across prior 
seasons, ≥2 doses recorded across prior seasons, and receipt of 2 doses within the same prior 
season. To test for priming we examine the conditional hypothesis that the effect of current 
season vaccine varies depending on prior vaccination history; we examine an interaction 
term for receipt of current season IIV3 by receipt of prior doses after adjusting for both 
contributing terms [21, 45, 46]. We estimate VE for each combination of current season and 
prior doses with those unvaccinated in the current season and not meeting the priming 
criteria as the reference group [21, 45–47]. We also test for differences between VE 
estimates (e.g., VE of fully vs. partially vaccinated; VE for primed vs. unprimed children) 
by calculating the odds ratio with one of the two vaccine exposures as the referent.
We estimate that 89 cases are needed to achieve 80% power (α = .05) to detect a VE of 50% 
with an influenza positivity rate of 33% and a vaccination rate of 50% among influenza 
negative controls. We meet or exceed these criteria in most estimates of VE for fully 
vaccinated children and those with common prior vaccination exposures (e.g., current season 
dose plus 1 or more prior doses). However, we have lower power to estimate VE for partially 
vaccinated children and for those with less common prior vaccination exposures. We 
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consider as noteworthy consistent patterns of results across models, but there is no 
adjustment for familywise error. Statistical analyses were conducted using SAS statistical 
software (version 9.3; SAS Institute, Cary, North Carolina).
RESULTS
Participant Characteristics
During 2011–2012, 1562 children aged 6 months to 8 years were enrolled during weeks with 
local influenza virus circulation at the 5 Network sites; 30 (2%) with indeterminate 
vaccination status and 91 (6%) who received LAIV3 were excluded, resulting in an analysis 
sample of 1,441 children (Supplemental Figure B). During 2012–2013, 1732 children were 
enrolled; 227 (13%) with incomplete medical records, 30 (2%) with indeterminate 
vaccination status, and 148 (9%) who received LAIV3 were excluded, resulting in an 
analysis sample of 1327 children (Supplemental Figure C).
In the 2011–2012 season, influenza circulation began late and peaked in March and April; 
only 13% (190/1441) of enrolled children were influenza positive (Network site range = 6–
17%). In contrast, during the 2012–2013 season, circulation peaked in December and 
January, and influenza positives made up 38% (499/1327) of enrollees (site range = 8–55%). 
In both seasons, A(H3N2) viruses were prominent at most sites; influenza positivity 
increased with age and was higher among Black children (Table 1).
The proportion receiving ≥1 doses of IIV3 was similar in 2011–2012 and 2012–2013 (50% 
and 45%, respectively). However, the percentage of enrolled children who were vaccinated 
increased per month in 2012–2013, climbing from 34% in December to 54% in March 
(Table 1). In both seasons, vaccine coverage declined with age and was lower among Black 
children.
Potential confounders (associated with both vaccination and influenza positivity) identified 
in the descriptive analyses were age, race, month of enrollment, and Network site. All of 
these potential confounders were already included a priori in the adjusted models.
VE for Full and Partial Vaccination using ACIP Criteria
The majority of children who received at least 1 dose of IIV3 in 2011–2012 and 2012–13 
had sufficient prior doses to meet the definition of fully vaccinated according to ACIP 
criteria (81%, 591/726 and 79%, 473/596, respectively). Therefore, in analyses that 
combined children from both seasons, the vast majority of fully vaccinated children (79%, 
845/1064) had received a single dose of IIV3; the other 21% (219/1064) received 2 
recommended doses, and the vast majority of these were less than 2 years old (88%, 
193/219).
We observed significant unadjusted VE for both partial and full vaccination associated with 
all circulating influenza viruses (both seasons), A(H3N2) viruses (both seasons), and B 
influenza viruses (2012–2013 season) (Table 2). Adjusted VE point estimates were 11–31 
percentage points lower than the crude estimates. VE for full vaccination remained 
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significant in all models, but VE for partial vaccination was only significant in the 2012–
2013 models.
VE estimates for fully vaccinated children were not significantly higher than VE for partially 
vaccinated children in any of the models. In fact, the only significant difference noted was 
opposite of the expected direction; in 2012–2013, adjusted VE against A(H3N2) illness was 
significantly lower among fully vaccinated children (Table 2).
VE with Different Prior Vaccination Exposures
Among children aged 2–8 years, we examined four definitions of influenza vaccine priming 
(Table 3). Because VE estimates associated with 1 versus 2 current season doses of IIV3 
were similar (with wide and overlapping CIs) (Supplemental Table B), we defined current 
season vaccination as receipt of 1 or more doses for the following priming analyses. Without 
priming, we observed adjusted VE for ≥1 current season dose(s) of IIV3 that ranged from 
47% to 53% across the four influenza outcomes (Table 3).
In the first analysis, priming consisted of 1 or more doses of any influenza vaccine in the 
previous season only. We observed significant effect modification of current season VE by 
prior season priming in all models (i.e., interaction terms p-values < .1). This cross-season 
effect is driven by significant residual VE for children who received no current season IIV3 
but were vaccinated the previous season; this was noted in all models (VE range = 36–40%).
In the second and third analyses, we expanded the definition of priming to include ≥1 and 
then ≥2 doses recorded in any prior season (Table 3). However, we did not observe a 
significant interaction effect for current season IIV3 by prior vaccination history using either 
of these definitions. Nonetheless, for most of these models the only significant VE was 
observed for children with current and prior seasonal doses.
In the fourth analysis, only children who had received 2 doses in the same prior season were 
considered primed. We observed significant interaction terms for current season IIV3 by 2-
dose priming history against influenza outcomes in all four models (p-values < .05). 
Although we observed significant VE for current season IIV3 with or without priming, the 
VE point estimates were consistently higher for children who had received 2 doses in a prior 
season compared to those without (VE range of 58–80% vs. 33–42%, respectively) (Table 
3). This was statistically significant for VE against A(H3N2) illness; the odds of being 
A(H3N2) positive were 2.4-fold (95% CI = 1.4–4.3) higher among children who received 
IIV3 but were unprimed compared to children who received IIV3 after receiving 2 dose 
priming in a previous season. Although the referent category in this model included 
unvaccinated children with no record of prior vaccination and those with prior vaccinations 
but without 2 doses within the same season, we observed similar VE estimates when the 
referent group was limited to only unvaccinated children with no known prior vaccination 
(Supplemental Table C).
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DISCUSSION
In our study of children aged 6 months to 8 years receiving outpatient medical care for ARI 
during 2011–2012 and 2012–2013, we found that children aged 2–8 years who received 
IIV3 after receiving 2 priming doses of any influenza vaccine during the same previous 
season had significantly higher VE against A(H3N2) illness than children without 2 priming 
doses. Children with 2-dose priming also had high VE point estimates against ARI 
associated with all influenza viruses (in both seasons) and B viruses (2012–2013). The effect 
was most evident when we examined vaccine failure against A(H3N2) illness; among 
children aged 2–8 years who received IIV3, the odds of A(H3N2) illness despite vaccination 
were 2.4-fold higher among unprimed children compared to those who received 2 doses of 
vaccine in a previous season. Our findings are consistent with studies that observed better 
IIV3 immunogenicity following 2 doses, though this has been demonstrated most 
consistently among vaccine naïve infants and children younger than those in our analyses 
[14–20]. Nonetheless, our findings add support to recommendations by multiple 
international organizations to offer 2 doses of influenza vaccine during a child’s first season 
[34, 44] and suggests the preventive benefits of this initial investment may extend to future 
seasons.
We did not observe higher VE for children fully vs. partially vaccinated with IIV3 as defined 
by ACIP in any of our models. The relatively small number of partially vaccinated children 
combined with the need to adjust for potential confounding (by age, race/ethnicity, 
geography, and simultaneous changes in vaccine coverage and influenza circulation) made 
VE estimates for partially vaccinated children imprecise, especially for 2011–2012. 
Admittedly, the relevance of these observations is limited because during the study period 
ACIP recommendations for children aged 6 months through 8 years considered doses of 
vaccine containing the A(H1N1)pdm09 component specifically; yet, we observed few 
A(H1N1)pdm09 virus infections in our study.
Nonetheless, our finding of significant VE for both full and partial vaccination against ARI 
associated with all influenza viruses, A(H3N2) viruses, and B influenza viruses in 2012–
2013 is consistent with several prior studies [25–27]. In contrast, our observation that 
partially vaccinated children experienced higher VE against A(H3N2) illness than fully 
vaccinated children was unexpected and is difficult to interpret. Without a much larger 
sample, it is impossible to disentangle and examine separately the diverse influenza vaccine 
exposures that constitute partial vs. full vaccination. In the 2012–13 sample, for example, 
partially vaccinated children, as defined by US ACIP, include those with a single current 
season dose and at least four kinds of vaccination histories (e.g., no prior vaccination, only 1 
prior dose, ≥2 prior doses but without at least 1 dose before and 1 dose after July 2010). 
These differences in vaccine exposure are also likely interconnected with differences in 
children’s history of natural infections with influenza viruses. Nonetheless, the observed 
higher VE against A(H3N2) for partially vaccinated children warrants further investigation, 
especially given recent studies of children aged ≥9 years and adults that reported higher 
point estimates for VE against influenza A(H3N2) illness among those not vaccinated during 
the previous season [21, 41, 45, 46, 48, 49] or over the previous 5 seasons [48]. These future 
investigations should include measures of immune markers, such as pre-season A(H3N2) 
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antibodies. Indeed, Ohmit et al.’s household cohort study observed lower pre-season 
A(H3N2) antibody titers which corresponded to lower VE against A(H3N2) illness among 
those vaccinated in both the current and prior year compared to those vaccinated in the 
current season only [49].
Children who were vaccinated during the previous season but who missed IIV3 vaccination 
in the study season appeared to benefit from residual protection. VE point estimates of 36–
40% were noted for previously vaccinated children aged 2–8 years in all models; this was 
noted in both the first study season (2011–2012) when the prior year vaccine components 
had not changed, as well as in the second study year (2012–2013) when the A(H3N2) and B 
influenza components had changed [21, 36]. Our findings are consistent with observations of 
persistent influenza A virus antibodies in children [50] and recent observations of cross-
season VE among children [27] and adults [21, 36, 46, 48, 51].
From a methodological standpoint, our findings suggest that reports of VE for children 
should estimate VE for specific combinations of current and prior season(s)’ vaccine 
exposure, similar to recent recommendations for the presentation of VE estimates for adults 
[21, 36, 46, 48]. This would also aid in VE comparisons across countries, where definitions 
of full and partial vaccination vary. In regards to vaccine policy, our findings combined with 
earlier observations of persistent protection offered by Spring (post-season) doses of IIV3 
[17, 52] suggest there may be value in considering alternative vaccine schedules that take 
advantage of opportunities to vaccinate young children months before influenza season, 
especially when vaccine components are unchanged. This may be especially relevant in 
countries and regions with year-round or twice-yearly influenza circulation [53].
Among the strengths of our study is our use of RT-PCR confirmed influenza outcomes with 
a test-negative design [42, 43, 54] in a multi-site study using a common protocol and 
procedures that directly recruited children receiving outpatient care for ARI without relying 
on clinician referral. Our ability to stratify results for A(H3N2) and B influenza virus 
illnesses improved the specificity of our results. Other study strengths include our ability to 
examine multiple years of vaccination records from health plan and state registries and the 
fact that ACIP recommendations for annual seasonal vaccination had consistently applied to 
all the children in our study.
Our study is limited by several potential sources of information bias. We only documented 
up to 4 prior vaccination records. While it is reasonable to assume that most children 
receiving 2 doses in the same season were vaccine naïve prior to that, we cannot confirm 
this. We also could not examine the cumulative total of all influenza vaccinations. Also, we 
may have falsely classified some of the children as unprimed due to incomplete vaccination 
records. Although our Network now documents all influenza vaccination records of 
enrollees, in the current study we could not verify the completeness of medical records for 
children during the 2011–2012 season. In an attempt to remove monovalent A(H1N1)pdm09 
vaccinations, we likely excluded some seasonal influenza vaccinations administered after 
October 2009. Taken together, these potential sources of information bias would result in 
underestimation of VE associated with full vaccination or multi-dose priming, especially 
among older children for whom more records need to be captured. Thus, although we are 
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confident in the significant effects we observed, these information biases combined with 
small sample sizes for some vaccine exposures reduced the precision of our estimates and 
likely limited our ability to detect true differences in VE.
In addition, our study has at least four other limitations. First, although we excluded children 
who received LAIV3 during the study season, we could not determine the vaccine types of 
all previous vaccinations. However, LAIV3 has accounted for a relatively small proportion 
of vaccinations in our Network to date [21, 25, 36]. Second, unmeasured or residual 
confounding may have biased our results in unknown ways, since children who consistently 
receive recommended influenza vaccination doses may differ from those who do not in 
susceptibility to influenza, access to medical care, and other characteristics. Third, we lack 
information on past infections and possible immune mechanisms that could explain the 
differences in clinical protection we observed. Finally, given limitations in our sample size 
and the number of prior vaccination records we retrieved, we were unable to examine VE 
associated with other potentially valuable priming histories. For example, future studies 
should examine whether 2 doses of vaccine in consecutive seasons when A(H3N2) vaccine 
components were unchanged offer similar priming value in reducing the risk of A(H3N2) 
illness as the receipt of 2 homologous doses in the same year.
In conclusion, during 2011–12 and 2012–13, vaccination with IIV3 reduced the risk of 
outpatient medical visits for ARI associated with influenza virus infection by about half. 
Vaccinations received in previous seasons had preventive value in subsequent seasons in the 
form of residual protection for those who missed vaccination in and priming which boosted 
the benefit of IIV. Most notably, children primed with 2 doses of influenza vaccine in the 
previous same season appeared to enjoy even greater preventive benefit from IIV3 and may 
have reduced their risk of A(H3N2) illness by two-thirds. Taken together, our findings 
reinforce the importance of examining influenza VE among children within the context of 
prior vaccination history and priming. Observational studies (and possibly randomized 
controlled trials in countries without universal vaccination recommendations for children) 
are needed to confirm the importance of priming doses to immunogenicity and VE and to 
inform international vaccine policy.
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0
5
(
4
)
80
(49
–
93
)
14
0
28
(
20
)
58
(32
–
75
)
26
2
15
(
6
)
70
(47
–8
3)
12
8
16
(
13
)
68
(21
–
77
)
N
ot
e:
 N
on
-z
er
o 
V
E 
es
tim
at
es
 (w
ith
 95
% 
co
nfi
de
nc
e 
in
te
rv
al
s [
CI
] t
ha
t d
o n
ot 
ov
er
la
p 
w
ith
 z
er
o) 
are
 bo
lde
d.
a T
o
ta
ls 
ex
cl
ud
e 
ch
ild
re
n 
w
ith
 il
ln
es
se
s a
ss
oc
ia
te
d 
w
ith
 in
flu
en
za
 B
 v
iru
se
s, 
A
(H
1N
1)p
dm
09
 vi
rus
, o
r u
ns
ub
typ
ed
 A
 vi
rus
es.
 Fo
r 
se
as
o
n
 2
01
2–
13
, t
he
re
 w
er
e 
3 
in
flu
en
za
 A
(H
3N
2) 
an
d B
 co
inf
ec
tio
ns
 th
at 
we
re 
ex
cl
ud
ed
. T
hu
s, 
th
e 
pe
rc
en
ta
ge
 in
flu
en
za
 p
os
iti
v
e 
(F
lu+
) i
s s
im
ply
 th
e 
n
u
m
be
r o
f A
(H
3N
2) 
illn
ess
es 
div
id
ed
 b
y 
th
e 
su
m
 o
f i
nf
lu
en
za
 n
eg
at
iv
es
 a
n
d 
A
(H
3N
2) 
po
sit
ive
s.
 T
hi
s i
s p
re
se
nt
ed
 a
s a
n 
ill
us
tra
tio
n 
to
 a
id
 in
te
rp
re
tin
g 
V
E.
b T
o
ta
ls 
ex
cl
ud
e 
ch
ild
re
n 
w
ith
 il
ln
es
se
s a
ss
oc
ia
te
d 
w
ith
 in
flu
en
za
 A
 v
iru
se
s. 
Th
us
, t
he
 p
er
ce
nt
ag
e 
of
 c
hi
ld
re
n 
w
ho
 a
re
 in
flu
en
za
 B
 v
iru
s p
os
iti
v
e 
(F
lu 
B+
) i
s s
im
ply
 th
e n
um
be
r o
f i
nfl
ue
nz
 B
 vi
rus
 ill
ne
sse
s d
ivi
de
d 
by
 th
e 
su
m
 o
f i
nf
lu
en
za
 n
eg
at
iv
es
 a
n
d 
in
flu
en
za
 B
 p
os
iti
v
es
. 
Th
is 
is 
pr
es
en
te
d 
as
 a
n 
ill
us
tra
tio
n 
to
 a
id
 in
te
rp
re
tin
g 
V
E.
c M
od
el
s a
dju
ste
d f
or 
stu
dy
 si
te,
 m
on
th 
of 
en
rol
lm
en
t, a
ge
 (in
 m
on
ths
), h
igh
 ris
k s
tat
us,
 ra
ce/
eth
nic
ity
,
 
an
d 
da
ys
 fr
om
 il
ln
es
s o
ns
et
 to
 e
nr
ol
lm
en
t. 
Th
e 
m
od
el
 fo
r A
(H
3N
2) 
illn
ess
 al
so
 in
clu
de
d a
 va
ria
bl
e 
fo
r s
ea
so
n 
an
d 
an
 in
te
ra
ct
io
n 
te
rm
 fo
r s
ea
so
n 
by
 m
on
th
.
d F
o
r 
se
as
o
n
 2
01
1–
12
, p
rio
r s
ea
so
n 
is 
20
10
–1
1;
 fo
r s
ea
so
n 
20
12
–1
3,
 p
rio
r s
ea
so
n 
is 
20
11
–1
2;
 th
e 
pr
io
r v
ac
ci
ne
 c
ou
ld
 b
e 
in
ac
tiv
at
ed
 o
r l
iv
e 
at
te
nu
at
ed
. R
ec
ei
pt
 o
f m
on
ov
al
en
t A
(H
1N
1)p
dm
09
 va
cc
in
e 
w
as
 n
o
t i
nc
lu
de
d.
 U
nv
ac
ci
na
te
d 
ch
ild
re
n 
re
ce
iv
ed
 n
o 
va
cc
in
e 
in
 c
ur
re
nt
 n
or
 
pr
io
r s
ea
so
n.
e A
ny
 p
rio
r s
ea
so
n 
in
cl
ud
es
 a
ny
 se
as
on
al
 v
ac
ci
na
tio
n 
re
ce
iv
ed
 p
rio
r t
o 
th
e 
cu
rre
nt
 st
ud
y 
se
as
on
 (e
ith
er 
20
11
–1
2 o
r 2
01
2–
13
). U
nv
ac
ci
na
te
d 
ch
ild
re
n 
re
ce
iv
ed
 n
o 
cu
rre
nt
 se
as
on
 II
V
3 
an
d 
ha
v
e 
n
o
 r
ec
o
rd
 o
f a
ny
 p
rio
r i
nf
lu
en
za
 v
ac
ci
na
tio
n.
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f P
rim
ed
 c
hi
ld
re
n 
ha
d 
re
co
rd
s c
on
fir
m
ed
 re
ce
ip
t o
f 2
 o
r m
or
e 
do
se
s s
um
m
ed
 a
cr
os
s p
rio
r s
ea
so
ns
; "
un
v
ac
ci
na
te
d 
an
d 
un
pr
im
ed
" c
hi
ld
re
n 
di
d 
no
t r
ec
ei
v
e 
cu
rr
en
t s
ea
so
n 
II
V
3 
an
d 
di
d 
no
t r
ec
ei
v
e 
2 
or
 m
or
e 
pr
ev
io
us
 d
os
es
 (b
u
t m
ay
 h
av
e 
ha
d 
1 
do
se
 in
 o
ne
 o
r m
or
e 
se
as
on
s).
g P
rim
ed
 c
hi
ld
re
n 
re
ce
iv
ed
 2
 d
os
es
 in
 a
 si
ng
le
 se
as
on
 p
rio
r t
o 
th
e 
stu
dy
 se
as
on
; "
un
v
ac
ci
na
te
d 
an
d 
un
pr
im
ed
" c
hi
ld
re
n 
di
d 
no
t r
ec
ei
v
e 
cu
rr
en
t s
ea
so
n 
II
V
3 
an
d 
di
d 
no
t h
av
e 
2 
do
se
s o
f a
ny
 in
flu
en
za
 v
ac
ci
ne
 in
 a
 si
ng
le
 p
rio
r s
ea
so
n 
(bu
t m
ay
 h
av
e 
ha
d 
2 
or
 m
or
e 
do
se
s a
cr
os
s m
ul
tip
le
 
pr
io
r s
ea
so
ns
).
h T
he
 o
dd
s o
f b
ei
ng
 A
(H
3N
2) 
po
sit
ive
 w
er
e 
2.
4-
fo
ld
 (9
5%
 C
I =
 1.
4–
4.3
) h
igh
er 
am
on
g c
hil
dre
n w
ho
 re
ce
ive
d 
IIV
3 
bu
t w
er
e 
un
pr
im
ed
 c
om
pa
re
d 
to
 c
hi
ld
re
n 
w
ho
 re
ce
iv
ed
 II
V
3 
af
te
r r
ec
ei
v
in
g 
2 
do
se
s i
n 
a 
pr
ev
io
us
 se
as
on
.
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